Effect of cisplatin and mitochondria transplantation isolated from human mesenchymal stem cells on DU-145 cell proliferation

Purpose: The aim of this study is to evaluate proliferation and cytotoxicity by applying the antineoplastic drug cisplatin and mitochondria isolated from human mesenchymal stem cells (IMSCs) to human prostate cancer cells (DU-145). Materials and Methods: IMSCs and DU-145 cell line were used in our study. IMSCs were multiplied to similar to 20x10(6) cells and mitochondria were isolated according to the protocols in kit. Protein content of the isolated mitochondria was measured by bicinchoninic acid method (BCA). DU-145 cells were seeded into 96-well plates at 10x10(3) cells in per well. Cisplatin 6 mu M and 14 mu M doses were administered for 24 hours. Isolated mitochondria (10x, 100x) were incubated for 24 hours again. Cell proliferation and viability were measured using the tetrazolium salt (MTT) method, and the absorbance values of 570 nm-630 nm were measured in a plate reader, and the cell proliferation percentages were calculated. Results: 6 mu M cisplatin application to DU-145 cells proliferation decreased by 35% compared to the control group, while 14 mu M cisplatin reduced it by 68%. When compared with the Cis-6 mu M group, there was no significant difference in proliferation in the Cis-6 mu M+Mito-10x group while a significant decrease was observed in the Cis-6 mu M+Mito-100x group. Conclusion: When mitochondria are transplanted together with cisplatin to prostate cancer cells, proliferation is further reduced. In addition, mitochondria transplantation may reduce the proliferation of cancerous cells by affecting various intracellular proliferative, apoptotic signaling pathways and by regulating the microenvironment.